Here, we have shown that administration of maraviroc attenuates gutinflammation in rodent models of colitis by selectively depleting CD11b+ CCR5+ cells from the colonic mucosa (in the TNBS model) and modulating the production of signature cytokines such as IL -1β, IL-6 and TNFα in both DSS-induced and TNBS models of colitis. Here, CCR5 is linked to colitis.